← Back to screener

Summit Therapeutics Inc. SMMT

Rank #2415 · Nasdaq · $12.4B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
19.8
P/E
-20.2
P/B
98.24
ROE
-485.5%
Op. Margin
–%
Debt Ratio
37%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -20.2x, P/B 98.24x. Ranks in the top 86% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -485.5%. Ranks in the top 99% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 37%. Ranks in the top 19% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.1B$0.0B$0.0B$-0.0B9.4-484
2021$0.0B$-0.1B$-0.1B$0.1B-6185.229
2022$0.0B$-0.1B$-0.1B$0.1B-4764.338
2023$0.0B$-0.1B$-0.1B$0.1B-10225.4645
2024$0.0B$-0.1B$-0.1B$0.1B-10225.4150
2025––$-0.6B$0.1B–37

← See the full screener